Monitor EHA 2026 presentations for ronde-cel safety and translational insights. Focus on PiNACLE trial data in H2 2026 and the Phase 3 PiNACLE-H2H trial for future valuation drivers.
LYEL drugs
LYEL drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jun 5 $11.97entry
- T+1 · 5mo ago +2.84%α +2.61% · $12.31
- T+5 · 5mo ago +12.78%α +12.21% · $13.50
- T+20 · 4mo ago +17.29%α +15.43% · $14.04
- T+60 · 3mo ago +19.63%α +15.63% · $14.32
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Lyell Immunopharma announced upcoming presentations of ronde-cel Phase 1/2 safety and translational data at the EHA 2026 Congress, but no clinical results were disclosed. The company's key catalysts remain the PiNACLE trial data expected in H2 2026 and a potential BLA submission in 2027. This is a routine pipeline update with no immediate impact.
Key Facts
- Ronde-cel safety and translational data to be presented at EHA 2026 (June 11-14).
- PiNACLE trial (3L+ LBCL) data expected H2 2026, pivotal data by mid-2027, BLA submission 2027.
- No new clinical data or financial guidance provided in this release.
Financial Impact
No financial impact from this filing; key catalysts are future data readouts.
Risk Factors
- Clinical data may not meet expectations; ronde-cel is still investigational.
- Competition from approved CAR-T therapies (Yescarta, Breyanzi).
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3307088 |
Track record
21 reports on LYEL
5 of 5 bullish or bearish reports moved the stock their way by T+1. Best: +17.99% at T+60 after the Jun 8, 2026 report. 5 of 5 went positive at some point.
Filters
- Nov 13, 20263d ago S-3 Neutral 3/10 Entry $14.30 Now $14.65 +2.45% settles Nov 17
- Nov 12, 20264d ago Insider Cluster Bullish 6/10 Entry $14.30 to $14.65 Now $14.65 +2.45% ▲ +2.45% +4.36% vs SPY
- Nov 10, 20266d ago SC 13G/A Neutral 2/10 Entry $16.86 to $15.64 Now $14.65 −13.11% ▼ −7.24% −6.88% vs SPY
- Nov 5, 202611d ago Insider Cluster Bullish 7/10 Entry $14.86 to $15.42 Now $14.65 −1.41% ▲ +3.77% +1.40% vs SPY
- Nov 4, 202612d ago 8-K Neutral 4/10 No price data
- Nov 4, 202612d ago Press Release Neutral 4/10 Entry $15.00 to $14.86 Now $14.65 −2.33% ▼ −0.93% −1.25% vs SPY
- Nov 4, 202612d ago 8-K Bearish 5/10 Entry $15.43 to $15.00 Now $14.65 +5.06% ▲ +2.79% −1.62% vs SPY
- Nov 4, 202612d ago Press Release Neutral 4/10 Entry $15.43 to $15.00 Now $14.65 −5.06% ▼ −2.79% +1.62% vs SPY
- Aug 25, 202611w ago Insider Cluster Neutral 4/10 Entry $14.80 to $14.61 Now $14.65 −1.01% ▼ −1.28% −1.94% vs SPY
- Jul 22, 202616w ago EFFECT Neutral 4/10 Entry $12.84 to $12.78 Now $14.65 +14.10% ▼ −0.47% +0.77% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers